Physician profile
Robert W Gilbert
NPI 1881685816
$412,010.55
in general payments reported to CMS, 2019-2025
54 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200K · 2020: $74K · 2021: $63K · 2022: $59K · 2023: $11K · 2024: $2,452 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,538 · Food and Beverage: $6,126 · Consulting Fee: $1,880 · Education: $24.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,537.50 |
| Food and Beverage | $6,126.00 |
| Consulting Fee | $1,880.00 |
| Education | $24.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68,905.59 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $64,445.07 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Genzyme Corporation | $57,761.58 | 2019-2025 | |
| Lilly USA, LLC | $50,851.39 | 2019-2024 | Emgality, Kisunla, Amyvid |
| Allergan, INC. | $45,188.42 | 2019-2021 | |
| Abbvie INC. | $33,752.90 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $24,635.06 | 2019-2025 | Kesimpta |
| Celgene Corporation | $22,487.43 | 2019-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $15,520.64 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $10,859.93 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company Ltd. | $9,244.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,632.14 | 2020-2022 | |
| Ucb, INC. | $774.92 | 2021-2025 | Briviact, Nayzilam, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $531.71 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $389.72 | 2019-2025 | Mavenclad |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $346.98 | 2023-2025 | |
| Sk Life Science, INC. | $297.96 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $247.31 | 2024-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $228.65 | 2022-2025 | Nuplazid, Daybue |
| Neurocrine Biosciences, INC. | $207.79 | 2022-2025 | Ingrezza |
| Biogen, INC. | $172.55 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Tg Therapeutics, INC. | $131.83 | 2023-2025 | |
| Lundbeck LLC | $128.77 | 2022-2024 | Vyepti |
| Eisai INC. | $126.43 | 2022-2025 | |
| Argenx US, INC. | $97.77 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Impel Pharmaceuticals INC. | $92.47 | 2022-2023 | Trudhesa |
| Kyowa Kirin, INC. | $83.53 | 2022-2024 | Nourianz |
| Acorda Therapeutics, INC | $73.57 | 2019-2024 | Inbrija |
| Amneal Pharmaceuticals LLC | $63.41 | 2023-2025 | Rytary, Crexont |
| Cycle Pharmaceuticals INC | $56.47 | 2024-2025 | Tascenso Odt |
| Supernus Pharmaceuticals, INC. | $55.19 | 2019 | |
| Vanda Pharmaceuticals INC. | $52.46 | 2024-2025 | Ponvory |
| Mdd US Operations, LLC | $48.55 | 2024 | Gocovri |
| Forte Bio-Pharma LLC | $44.44 | 2025 | Tanlor |
| Horizon Therapeutics Plc | $42.46 | 2023 | Uplizna |
| Azurity Pharmaceuticals, INC. | $35.04 | 2025 | Horizant |
| Avion Pharmaceuticals | $34.20 | 2023 | Dhivy |
| Janssen Biotech, INC. | $27.06 | 2025 | |
| Harmony Biosciences LLC | $26.14 | 2023 | Wakix |
| Adamas Pharmaceuticals, INC. | $25.71 | 2019-2020 | |
| Axsome Therapeutics, INC. | $25.00 | 2025 | Symbravo |
| Bausch Health US, LLC | $24.68 | 2020 | |
| Collegium Pharmaceutical, INC. | $24.31 | 2022 | |
| Kedrion Biopharma, INC. | $22.24 | 2024 | Gammaked, Kedrab, Koate |
| Upsher-Smith Laboratories LLC | $21.66 | 2022 | |
| Tanabe Pharma America, INC. | $20.14 | 2023 | |
| Csl Behring | $20.13 | 2023 | Hizentra |
| Astrazeneca Pharmaceuticals Lp | $19.85 | 2024 | Wainua |
| Ani Pharmaceuticals, INC. | $18.94 | 2023 | Purified Cortrophin Gel |
| Greenwich Biosciences, INC. | $18.45 | 2019 | |
| Zyla Life Sciences, INC. | $18.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.70 | 2019 | |
| Cala Health, INC. | $17.63 | 2023 | Cala Trio |
| Assertio Therapeutics, INC. | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.